385 related articles for article (PubMed ID: 33676425)
21. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
22. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
23. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
[TBL] [Abstract][Full Text] [Related]
24. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
25. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
[TBL] [Abstract][Full Text] [Related]
26. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Carter JM; Polley MC; Leon-Ferre RA; Sinnwell J; Thompson KJ; Wang X; Ma Y; Zahrieh D; Kachergus JM; Solanki M; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Thompson EA; Goetz MP
Clin Cancer Res; 2021 Oct; 27(20):5628-5637. PubMed ID: 34108182
[TBL] [Abstract][Full Text] [Related]
28. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
30. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
32. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
33. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
Vlajnic T; Baur F; Soysal SD; Weber WP; Piscuoglio S; Muenst S
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):726-730. PubMed ID: 36165931
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
Mirili C; Paydas S; Kilic EB; Seydaoglu G; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M; Ergin M; Zorludemir S
J BUON; 2020; 25(1):159-167. PubMed ID: 32277627
[TBL] [Abstract][Full Text] [Related]
36. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
Imanishi S; Morishima H; Gotoh T
Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
38. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
